Ozempic Appeal Letter Sample — Prior Authorization Denied
By AppealArmor | March 24, 2026 | 8 min read
When your Ozempic prior authorization is denied, a well-crafted appeal letter with the right clinical citations makes the difference between approval and rejection. This sample letter includes the specific elements that get GLP-1 appeals approved.
Ozempic PA Appeal Letter Template
[Physician Name, MD/DO]
[Practice Name]
[Address]
[Date]
[Insurance Company]
Pharmacy Appeals / Prior Authorization Appeals
[Address from denial letter]
Re: Appeal of Prior Authorization Denial — Ozempic (semaglutide)
Patient: [Name] | Member ID: [ID]
PA Reference: [Number] | Denied: [Date]
Rx: Ozempic (semaglutide) [dose] mg subcutaneous injection, weekly
NDC: [Number] | Diagnosis: Type 2 Diabetes Mellitus (E11.65)
Dear Pharmacy Appeals Committee:
I am writing to appeal the prior authorization denial for Ozempic (semaglutide) for my patient [name]. The denial stated [exact denial language]. I respectfully submit that this denial should be reversed for the following reasons.
Clinical Summary:
[Patient] is a [age]-year-old [male/female] with type 2 diabetes mellitus diagnosed [date], complicated by [list: cardiovascular disease, CKD, obesity, neuropathy]. Current A1C: [value]% (target: <7.0%). BMI: [value].
Medications Tried and Failed:
1. Metformin [dose] — [dates] — A1C remained [value]%, GI side effects required dose reduction
2. [Second agent] [dose] — [dates] — [specific outcome]
3. [Third agent if applicable] — [dates] — [specific outcome]
Why Semaglutide (Ozempic) Is Required:
The American Diabetes Association Standards of Medical Care (2026), Section 9, recommends GLP-1 receptor agonists with demonstrated cardiovascular benefit for patients with T2DM and established ASCVD or high cardiovascular risk. [Patient] meets this criterion based on [specific clinical evidence]. The SUSTAIN-6 trial demonstrated that semaglutide reduced major adverse cardiovascular events (MACE) by 26% (HR 0.74, 95% CI 0.58-0.95). Additionally, the SELECT trial confirmed cardiovascular risk reduction in patients with obesity regardless of diabetes status.
Consequences of Denial:
Without semaglutide, [patient] faces continued suboptimal glycemic control (current A1C [value]%), which increases the risk of [specific complications]. Delaying effective GLP-1 therapy in a patient with [cardiovascular risk / CKD / other] contradicts current evidence-based guidelines.
Requested Action:
I request immediate approval of Ozempic (semaglutide) [dose] for [patient]. If denied, please provide specific clinical rationale and notification of external review rights.
Sincerely,
[Physician Name, MD/DO]
NPI: [Number] | DEA: [Number]
[Phone] | [Fax]
Key Citations to Include
- ADA Standards of Care, Section 9: GLP-1 RA recommended for T2DM with ASCVD/CKD/HF, independent of A1C
- SUSTAIN-6 (NEJM 2016): Semaglutide reduced MACE by 26% vs placebo in T2DM patients
- SELECT (NEJM 2023): Semaglutide reduced cardiovascular events by 20% in patients with obesity
- CMS NCD for diabetes management: Medicare covers GLP-1 agonists for diabetes, establishing baseline coverage
Customizing This Template
This template must be adapted to your specific situation:
- If denied for step therapy: Emphasize the failed medication history section. Include pharmacy records as enclosures.
- If denied for medical necessity: Emphasize the ADA guideline citations and cardiovascular benefit data.
- If denied as non-formulary: Request a formulary exception and explain why the formulary alternative is clinically inappropriate for this patient.
- If the patient has cardiovascular disease: Lead with the SUSTAIN-6 and SELECT data. This is your strongest argument.
Pro Tip
Generic templates get generic responses. The most effective Ozempic appeals use the patient's actual lab values, specific medication history with dates and outcomes, and cite the exact insurer PA criteria being appealed. AppealArmor automatically pulls these elements from your denial letter and generates a fully personalized appeal.
Ready to Fight Your Denial?
AppealArmor generates Ozempic-specific appeals personalized to your denial letter, with ADA citations, SUSTAIN/SELECT trial data, and insurer-specific PA criteria.
Generate Your Appeal — Free